Monument Tx is a clinical stage biotech company applying a precision medicine approach to neuroscience drug development. Our proprietary digital biomarkers select the patients most likely to benefit from our novel formulations of CNS-active small molecules. Our lead programme, targeting neuroinflammation, is now in phase 1 while our second, aiming at cognitive impairment in schizophrenia, just finished preclinical. Monument is raising £15m in a Series A (early 2023) to complete clinical proof-of-mechanism studies in these two programmes in 2024. We expect ROI from pharma out-licensing or exit opportunities from 2025 on. Our pipeline reflects our expertise in cognitive function, with research collaborations in place for post-operative cognitive decline, ADHD, autism, and 'brain fog' related to chemotherapy and to long COVID.